ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,116.17
0.32%
Dow Jones
38,386.09
0.00%
US Dollar vs MXN
16.9647
-0.29%
Brent Oil
87.685
0.46%
Bitcoin
60,908.69
-4.59%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Eagle Pharmaceuticals Inc (EGRX)

  7. Eagle Pharmaceuticals Inc (EGRX) Noticias

EGRX Eagle Pharmaceuticals Inc

4.05
0.00 (0.00%)
Pre Mercado
Última actualización: 04:53:07
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Eagle Pharmaceuticals Inc EGRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 4.05 04:53:07
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.05
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/3/202415:49EDGAR2Form 8-K - Current report
01/3/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202406:35EDGAR2Form 8-K - Current report
29/2/202419:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202407:09EDGAR2Form 8-K - Current report
14/2/202416:09EDGAR2Form SC 13D - General statement of acquisition of beneficial..
13/2/202414:53EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202407:50EDGAR2Form 8-K - Current report
09/2/202404:45PRNUSEagle Pharmaceuticals, Inc. Securities Fraud Class Action..
07/2/202408:15EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202404:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
26/1/202404:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
19/1/202404:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
18/1/202405:56EDGAR2Form 8-K - Current report
18/1/202405:50GLOBEEagle Pharmaceuticals Provides Update on Bendamustine..
16/1/202406:00EDGAR2Form 8-K - Current report
12/1/202404:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
09/1/202416:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202404:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
22/12/202318:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202316:15EDGAR2Form 8-K/A - Current report: [Amend]
20/12/202315:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
15/12/202316:11EDGAR2Form 8-K - Current report
06/12/202315:26EDGAR2Form 8-K - Current report
06/12/202315:05GLOBEEagle Pharmaceuticals to Present Abstract on Post-hoc..
29/11/202306:39EDGAR2Form 8-K - Current report
29/11/202306:36EDGAR2Form 8-K - Current report
09/11/202316:23EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
09/11/202306:57EDGAR2Form 8-K - Current report
09/11/202306:30GLOBEEagle Delays Third Quarter 2023 Results and Conference Call
08/11/202307:30GLOBEEagle Pharmaceuticals to Host Third Quarter 2023 Financial..
03/11/202315:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202315:53EDGAR2Form 144 - Report of proposed sale of securities
01/11/202316:02EDGAR2Form 144 - Report of proposed sale of securities
31/10/202316:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/10/202307:49EDGAR2Form 8-K - Current report
24/10/202307:40GLOBEEagle Pharmaceuticals Granted Patent for PEMFEXY®
23/10/202306:10EDGAR2Form 8-K - Current report
23/10/202305:50GLOBEEagle Pharmaceuticals Granted Unique J-Code and Pass-Through..
04/10/202316:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202305:50GLOBEEagle Pharmaceuticals Awarded First Prize for Poster to Be..
03/10/202315:48EDGAR2Form 144 - Report of proposed sale of securities
02/10/202315:51EDGAR2Form 144 - Report of proposed sale of securities
27/9/202306:00EDGAR2Form 8-K - Current report
19/9/202315:05GLOBEEagle Pharmaceuticals to Present at the Cantor Global..
11/9/202305:50GLOBEEagle Pharmaceuticals to Present CAL02 Trial in Progress at..

Su Consulta Reciente

NASDAQ
EGRX
Eagle Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados